Integrated Diagnostics Holdings plc
(the
"Company")
Cancellation of Treasury Shares
08 October 2024
The Company today announces the
cancellation of 18,673,728 treasury shares initially transferred to
treasury on the Completion of
Treasury Shares Removal Process referred to in the Company's
announcement on 18 September 2024.
In accordance with Listing Rule
9.8.2 the Company discloses the following information:
|
Date of cancellation
|
08 October 2024
|
|
Number of ordinary shares held in
treasury cancelled
|
18,673,728
|
|
Total number of ordinary shares held
in treasury following the cancellation
|
0
|
|
Total number of ordinary shares in
issue following the cancellation (excluding shares held in
treasury)
|
581,326,272
|
For further information please
contact:
Integrated Diagnostics Holdings
plc
Tarek Yehia
Investor Relations
Director
T: +20 (0)2 3332 1126 | M: +20 10
6882 6678 | tarek.yehia@idhcorp.com
Company Secretary
Company Matters
IDHLondon@linkgroup.co.uk
-Ends-
About Integrated Diagnostics
Holdings (IDH)
IDH is
a leading diagnostics services provider in the Middle East and
Africa offering a broad range of clinical pathology and radiology tests to
patients in Egypt, Jordan, Nigeria, Sudan and Saudi Arabia.
The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in
Egypt, as well as Biolab (Jordan), Echo-Lab
(Nigeria), Ultralab and Al Mokhtabar Sudan (both in
Sudan), and Biolab KSA (Saudi Arabia).
With over 40 years of experience, a long track record for quality
and safety has earned the Company a trusted reputation, as well as
internationally recognised accreditations for its portfolio of
over 3 ,000
diagnostics tests. From its base of 601 branches as of 31
December 2023, IDH
served over 8. 5 million
patients and performed more than 36.1 million tests in 2023. IDH will continue to add
laboratories through a Hub, Spoke and Spike business model that
provides a scalable platform for efficient expansion. Beyond
organic growth, the Group targets expansion in appealing markets,
including acquisitions in the Middle Eastern, African, and
East Asian markets where its model is well-suited to capitalise on
similar healthcare and consumer trends and capture a significant
share of fragmented markets. IDH is a Jersey-registered
entity whose Shares are admitted to the equity shares (transition)
category (previously, the standard listing segment) of the Official
List of the UK Financial Conduct Authority and admitted to trading
on the main market for listed securities of the London Stock
Exchange since May 2015 (ticker: IDHC).
Learn more at idhcorp.com.